PARAGON CARE LIMITED (PGC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PGC

PGC - PARAGON CARE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.47
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.315

17 Sep
2025

0.000

OPEN

$0.32

0.000

HIGH

$0.33

124,851

LOW

$0.32

TARGET
$0.485 54.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
PGC: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 1.2 2.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx 37.8% 65.3% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 14.9 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 18/09 - ex-div 0.6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx1.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx3,613.9 M
Book Value Per Share xxxxxxxxxxxxxxx19.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.3 M
Net Profit Margin xxxxxxxxxxxxxxx0.57 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx6.74 %
Return on Invested Capital xxxxxxxxxxxxxxx4.14 %
Return on Assets xxxxxxxxxxxxxxx1.73 %
Return on Equity xxxxxxxxxxxxxxx6.74 %
Return on Total Capital xxxxxxxxxxxxxxx9.57 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-23.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx48 M
Long Term Debt xxxxxxxxxxxxxxx249 M
Total Debt xxxxxxxxxxxxxxx297 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx1.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx16.9 M
Capex % of Sales xxxxxxxxxxxxxxx0.47 %
Cost of Goods Sold xxxxxxxxxxxxxxx3,462 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx97 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

29/08/2025

1

Buy

$0.47

49.21%

Paragon Care's FY25 revenue of $3,614m was up 8.3% year-on-year but -4% below Bell Potter’s forecast. Gross margins held at 9%, though the revenue shortfall meant earnings of $95.2m came in -2.6% below the broker's expectations.

Adjusting for merger-related amortisation and integration costs, normalised EBIT was around 7% ahead of forecasts, explain the analysts.

Operating cash flow (OCF) was negative -$11.3m due to a $56m increase in receivables, largely from retail pharmacy debtors, explains Bell Potter. Recovery is expected in FY26, according to management.

 Cost synergies of $5m were delivered in FY25, with a further $12m targeted for FY26.

The broker trims FY26 its EPS forecast by -7% due to higher finance costs. The target price is reduced to 47c from 52c. Bell Potter retains a Buy rating.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.00 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

PGC STOCK CHART

FNArena News on PGC

1
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View
2
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
3
Weekly Ratings, Targets, Forecast Changes – 23-05-25

May 26 2025 - Weekly Reports
4
FNArena Corporate Results Monitor – 28-02-2025

Feb 28 2025 - Australia
5
Weekly Ratings, Targets, Forecast Changes – 22-11-24

Nov 25 2024 - Weekly Reports

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia